Selected article for: "clinical outcome and previous study"
Author: Daniela Weiskopf; Katharina S. Schmitz; Matthijs P. Raadsen; Alba Grifoni; Nisreen M.A. Okba; Henrik Endeman; Johannes P.C. van den Akker; Richard Molenkamp; Marion P.G. Koopmans; Eric C.M. van Gorp; Bart L. Haagmans; Rik L. de Swart; Alessandro Sette; Rory Dylan de Vries
Title: Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
  • Document date: 2020_4_18
    • ID: 97gme3pl_19
    Snippet: Novel SARS-CoV-2 vaccines are currently in development and mainly focus on the surface glycoprotein S as an antigen for efficient induction of virus-specific neutralizing antibodies. We now show that S can also be a potent immunogen for inducing virus-specific CD4 + and CD8 + T-cells, and our data combined with a previous study in a non-severe, recovered, COVID-19 patient 6 , indicate that virusspecific T-cells could be beneficial for a good clin.....
    Document: Novel SARS-CoV-2 vaccines are currently in development and mainly focus on the surface glycoprotein S as an antigen for efficient induction of virus-specific neutralizing antibodies. We now show that S can also be a potent immunogen for inducing virus-specific CD4 + and CD8 + T-cells, and our data combined with a previous study in a non-severe, recovered, COVID-19 patient 6 , indicate that virusspecific T-cells could be beneficial for a good clinical outcome. Collectively, these novel data are important for vaccine design and will facilitate the evaluation of future vaccine immunogenicity. All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • clinical outcome and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • clinical outcome and SARS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • clinical outcome and vaccine design: 1, 2, 3, 4, 5, 6
    • clinical outcome and vaccine immunogenicity: 1, 2
    • efficient induction and SARS vaccine: 1, 2, 3
    • efficient induction and vaccine design: 1
    • efficient induction and vaccine immunogenicity: 1
    • future vaccine immunogenicity and vaccine immunogenicity: 1, 2
    • neutralize antibody and SARS vaccine: 1, 2, 3, 4, 5
    • neutralize antibody and vaccine design: 1, 2, 3, 4
    • neutralize antibody and vaccine immunogenicity: 1, 2, 3
    • Novel SARS vaccine and previous study: 1
    • Novel SARS vaccine and SARS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • Novel SARS vaccine and vaccine design: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • Novel SARS vaccine and vaccine immunogenicity: 1, 2
    • potent immunogen and SARS vaccine: 1
    • potent immunogen and vaccine design: 1, 2, 3
    • potent immunogen and vaccine immunogenicity: 1, 2
    • previous study and vaccine immunogenicity: 1, 2, 3, 4